SCHEMBL7404029

SCHEMBL7404029

COC(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CN(Cc1ccc(-c2ccccc2)cc1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)C

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
UGT1A1 P22309 3/20 0.74
MLNR O43193 1/20 0.74
NR1I2 O75469 1/20 0.74
SLCO2B1 O94956 1/20 0.74
ABCB11 O95342 1/20 0.74
ABCB1 P08183 1/20 0.74
CCKAR P32238 1/20 0.74
OPRK1 P41145 1/20 0.74
GHSR Q92847 1/20 0.74
SLCO1B3 Q9NPD5 1/20 0.74
ABCG2 Q9UNQ0 1/20 0.74
SLCO1B1 Q9Y6L6 1/20 0.74
KCNH2 Q12809 1/20 0.56
PSEN1 P49768 9/20 0.51
PSEN2 P49810 9/20 0.51
APH1B Q8WW43 9/20 0.51
NCSTN Q92542 9/20 0.51
APH1A Q96BI3 9/20 0.51
PSENEN Q9NZ42 9/20 0.51
CYP3A4 P08684 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7404435 0.97 UGT1A1 (0.74) UGT1A1MLNRNR1I2SLCO2B1ABCB11
SCHEMBL29623988 0.95 UGT1A1 (0.81) UGT1A1MLNRNR1I2SLCO2B1ABCB11
SCHEMBL7284198 0.93 UGT1A1 (0.63) UGT1A1MLNRNR1I2SLCO2B1ABCB11
SCHEMBL7284205 0.93 UGT1A1 (0.63) UGT1A1MLNRNR1I2SLCO2B1ABCB11
SCHEMBL6253 0.91 UGT1A1 (0.91) UGT1A1MLNRNR1I2SLCO2B1ABCB11
SCHEMBL7546023 0.91 MLNR (0.61) UGT1A1MLNRNR1I2SLCO2B1ABCB11
SCHEMBL7489924 0.90 UGT1A1 (0.66) UGT1A1MLNRNR1I2SLCO2B1ABCB11
SCHEMBL6108 0.89 UGT1A1 (0.71) UGT1A1MLNRNR1I2SLCO2B1ABCB11
SCHEMBL6749 0.89 UGT1A1 (0.67) UGT1A1MLNRNR1I2SLCO2B1ABCB11
SCHEMBL7405607 0.89 UGT1A1 (0.65) UGT1A1MLNRNR1I2SLCO2B1ABCB11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0876336-B1 AZAHEXANE DERIVATIVES AS SUBSTRATE ISOSTERS OF RETROVIRAL ASPARATE PROTEASES NOVARTIS AG (CH) 2002-06-05 EP claimed
US-6225345-B1 FOR THERAPY OF ACQUIRED IMMUNODEFICIENCY SYNDROME NOVARTIS AG (CH) 2001-05-01 US claimed
EP-0876336-A1 AZAHEXANE DERIVATIVES AS SUBSTRATE ISOSTERS OF RETROVIRAL ASPARATE PROTEASES Novartis AG (CH) 1998-11-11 EP claimed
WO-1997019055-A1 AZAHEXANE DERIVATIVES AS SUBSTRATE ISOSTERS OF RETROVIRAL ASPARATE PROTEASES NOVARTIS AG (CH) 1997-05-29 WO claimed
EP-0876336-B1 AZAHEXANE DERIVATIVES AS SUBSTRATE ISOSTERS OF RETROVIRAL ASPARATE PROTEASES NOVARTIS AG (CH) 2002-06-05 EP disclosed
US-6225345-B1 FOR THERAPY OF ACQUIRED IMMUNODEFICIENCY SYNDROME NOVARTIS AG (CH) 2001-05-01 US disclosed
EP-0876336-A1 AZAHEXANE DERIVATIVES AS SUBSTRATE ISOSTERS OF RETROVIRAL ASPARATE PROTEASES Novartis AG (CH) 1998-11-11 EP disclosed
WO-1997019055-A1 AZAHEXANE DERIVATIVES AS SUBSTRATE ISOSTERS OF RETROVIRAL ASPARATE PROTEASES NOVARTIS AG (CH) 1997-05-29 WO disclosed